GLS and ovarian neoplasm: GLS1‐targeted siRNA significantly decreased cancer growth and invasion in mice bearing ovarian tumors derived from glutamine‐dependent (high‐invasive, SKOV3ip1) compared to glutamine‐independent (low‐invasive, IGROV1) cells.